Primarily based on the advice of the Nomination and Remuneration Committee, the Board of Administrators of Eris Lifesciences Restricted have handed a round decision on December 19, 2020, approving appointment of Mr. Rajeev Dalal (DIN : 00222650) as an “Extra Director (Non‐Government Impartial Director)” on the Board of Administrators of the Firm with impact from December 19, 2020 for a time period of 5 (5) years upto December 18, 2025, topic to approval of the Shareholders of the Firm.
Profile Abstract of Mr. Rajeev Dalal: Mr. Rajeev Dalal is a Member of the Institute of Firm Secretaries of India. Additional he additionally holds diploma of Bachelor of Legislation and Bachelor of Commerce. He has additionally been a member of the Committee appointed by the Securities Alternate Board of India (SEBI) for bettering disclosure requirements in public paperwork of Corporates for Capital points. He has over 35 years of Company Finance expertise protecting 100+ M&A (home and cross border) transactions and Personal Fairness offers in sectors resembling Pharma, Chemical compounds, FMCG, Metals & Mining, Industrials and Monetary Providers. He was related to Ernst & Younger LLP as transactions accomplice in 2002, previous to that he was related to Ind International Finance Belief (a class 1 funding financial institution), HSBC and JM Monetary of their funding banking divisions.
Mr. Rajeev Dalal will not be associated to another current Director of the Firm and isn’t debarred from holding the workplace by advantage of any SEBI Order or another authority.
Shares of Eris Lifesciences Ltd was final buying and selling in BSE at Rs.567 as in comparison with the earlier shut of Rs. 564.95. The whole variety of shares traded in the course of the day was 9498 in over 716 trades.
The inventory hit an intraday excessive of Rs. 574.9 and intraday low of 550. The web turnover in the course of the day was Rs. 5351715.